Basic Macrodantin Information

• INN (International Nonproprietary Name): Nitrofurantoin.
• Brand Names Available In United Kingdom: Macrobid (100 mg extended‑release) is explicitly listed as available in the UK; Furadantin and Furabid are listed for Europe and may be supplied in UK markets.
• ATC Code: J01XE01.
• Forms & Dosages: Capsules 25 mg, 50 mg and 100 mg; 100 mg extended‑release capsules; tablets 100 mg; oral suspension 25 mg/5 mL and 50 mg/5 mL for paediatric use.
• Manufacturers In United Kingdom: Major suppliers to the UK/EU markets include Mylan, Sandoz, Teva and Astellas.
• Registration Status In United Kingdom: Prescription only, with regulatory approval recorded in Europe and referenced by EMA listings.
• OTC / Rx Classification: Prescription only (Rx).

Latest Research Highlights (UK & EU 2022–2025)

Clinicians ask whether nitrofurantoin still belongs as a first‑line choice for uncomplicated urinary tract infection.

Recent UK and EU surveillance and clinical research from 2022–2025 reinforce nitrofurantoin’s role as a first‑line oral option for uncomplicated lower urinary tract infection in non‑pregnant adults.

Public surveillance reports from UKHSA and ECDC show persistently low community Escherichia coli resistance to nitrofurantoin compared with older agents such as trimethoprim and ciprofloxacin.

Randomised outpatient trials comparing multi‑day nitrofurantoin regimens with single‑dose fosfomycin report non‑inferiority for symptom resolution in women with uncomplicated cystitis.

Regulatory safety reviews from EMA and MHRA since 2022 highlight rare but important risks with prolonged or repeated nitrofurantoin courses.

Reported safety signals include chronic pulmonary reactions, hepatic injury and peripheral neuropathy, prompting guidance to assess renal function in older adults before treatment.

Below is a concise study summary to aid prescribers and pharmacists when counselling patients.

• Clinical Outcomes: microbiological cure, symptom resolution and recurrence rates reported as comparable between multi‑day nitrofurantoin and oral fosfomycin regimens in outpatient women.
• Safety Findings: rare pulmonary and neurological events associated with long courses or repeated suppressive therapy; hepatic reactions reported but uncommon.
• Surveillance Notes: UKHSA/ECDC community surveillance documents consistently lower E. coli resistance to nitrofurantoin than to trimethoprim.

Key sources to consult when updating local formularies include MHRA and EMA safety communications, UKHSA and ECDC resistance reports, and recent randomised trials and systematic reviews.

Clinical Effectiveness In The UK (NHS Outcomes)

Patients want to know how quickly they will feel better on nitrofurantoin.

NHS practice‑level data and patient‑reported outcomes show high rates of symptomatic improvement for uncomplicated cystitis when nitrofurantoin is started promptly and taken as directed.

Primary‑care audits from GP clusters and NHS e‑prescribing data demonstrate lower re‑consultation and second‑antibiotic rates for nitrofurantoin compared with trimethoprim.

This pattern reflects better empirical coverage against current urinary E. coli strains circulating in the community.

Effectiveness is limited for pyelonephritis and suspected upper tract or prostate infection because nitrofurantoin achieves low tissue penetration outside the urinary tract.

In elderly patients and those with renal impairment outcomes are confounded by contraindications and dose restrictions, which NHS guidance highlights using eGFR thresholds.

Clinical caveat: culture and local susceptibility patterns should inform antibiotic choice in recurrent or complicated infections.

Patient Outcomes (highlights):

• Rapid symptomatic relief in most uncomplicated cystitis when therapy is started within 48 hours of symptom onset.
• Lower re‑consultation and second‑antibiotic prescriptions versus trimethoprim seen in primary‑care audits.
• Not suitable for upper urinary tract infection, prostatitis or systemic infection.

Indications And Expanded Uses (MHRA And NHS Practice)

Patients often ask whether nitrofurantoin can be used to prevent repeated bladder infections.

MHRA and NHS formularies list nitrofurantoin primarily for treatment and prophylaxis of uncomplicated lower urinary tract infections (cystitis).

Common pragmatic uses in UK practice include short‑term prophylaxis for recurrent cystitis when alternatives are unsuitable.

Specialist paediatric dosing is used from age one month and above under paediatric or infectious disease advice.

Nitrofurantoin is not recommended for pyelonephritis, prostatitis or systemic infections due to limited tissue penetration.

When used for suppression, clinicians commonly prescribe bedtime doses of 50–100 mg after culture confirmation.

Prolonged suppressive courses require a risk assessment and monitoring for peripheral neuropathy and pulmonary effects.

MHRA‑Approved Indication: treatment and prophylaxis of uncomplicated lower urinary tract infections.

Common Off‑Label Or Pragmatic Uses:

• Short‑term nightly prophylaxis for recurrent cystitis following culture confirmation.
• Paediatric treatment by specialist teams for children aged ≥1 month with weight‑based dosing.

Checklist For When To Culture Or Send Susceptibility:

• Recurrent infections (two or more episodes in six months).
• Failure of first‑line therapy or persistent symptoms after treatment.
• Complex comorbidity, pregnancy outside uncomplicated scenarios, or recent antibiotic exposure.

Composition And Brand Landscape (UK Market)

Patients sometimes ask whether Macrobid is different from standard nitrofurantoin capsules.

The active ingredient is nitrofurantoin in all listed products.

Brand forms noted in the raw product information include Furadantin, Macrodantin, Macrobid and Furabid, with Macrobid documented as available in the UK market as a 100 mg extended‑release product.

Pharmaceutical forms sold include capsules (25 mg, 50 mg, 100 mg), 100 mg extended‑release capsules and oral suspension in 25 mg/5 mL or 50 mg/5 mL for paediatric use.

Major manufacturers supplying UK and EU markets are Mylan, Sandoz, Teva and Astellas, with a wide range of generic suppliers also present.

All formulations are prescription only.

Brand Notes:

• Macrobid is a modified‑release 100 mg formulation and may be dosed differently to immediate‑release nitrofurantoin tablets or capsules.
• Furadantin appears in EU labelling and is supplied in capsule and suspension forms.

Practical Box: community chemists and online pharmacies typically stock generics and, where available, Macrobid as the modified‑release option.

Contraindications And Special Precautions (High‑Risk Groups)

Clinicians must screen for renal function and pregnancy before prescribing nitrofurantoin.

Absolute contraindications include severe renal impairment with CrCl or eGFR below 30 mL/min, known allergy to nitrofurantoin, previous jaundice or hepatic dysfunction attributed to the drug, late pregnancy from 38 weeks and infants under one month.

Relative cautions include G6PD deficiency because of haemolysis risk, advanced age due to higher risk of pulmonary and neurological adverse effects, vitamin B deficiency and pre‑existing peripheral neuropathy.

Practical lifestyle advice for patients includes warning about transient brown urine and advising caution with driving if feeling dizzy.

Alcohol is not formally contraindicated but may worsen gastrointestinal upset and affect adherence, so counsel moderation.

Contraindications (Bulleted):

• Severe renal impairment (CrCl/eGFR <30 mL/min).
• Known hypersensitivity to nitrofurantoin.
• History of nitrofurantoin‑related jaundice or liver injury.
• Pregnancy from 38 weeks to delivery and infants <1 month.

Decision Flow For Prescribers (Short):

• Check renal function first (eGFR/CrCl).
• Confirm pregnancy status and neonatal risk if late pregnancy.
• Review comorbid neuropathy, liver disease and G6PD status.

Dosage Guidelines (NHS‑Aligned Regimens)

Patients frequently ask about how many times a day they must take nitrofurantoin.

Standard adult dosing for uncomplicated urinary tract infection in UK practice is 50–100 mg every six hours, taken four times daily for seven days for acute infections.

For prophylaxis the usual regimen is 50–100 mg at bedtime as a suppressive dose.

Modified‑release Macrobid 100 mg is often prescribed twice daily according to the product SmPC.

Paediatric dosing from one month of age is weight based at about 5–7 mg/kg/day divided into four doses using the oral suspension where required.

Do not use nitrofurantoin if eGFR is under 30 mL/min; renal function testing is advised in the elderly and those with comorbid renal disease.

Dosage Comparison Table (Simple):

• Adult Acute: 50–100 mg every 6 hours for 7 days.
• Prophylaxis: 50–100 mg at bedtime.
• Paediatric: 5–7 mg/kg/day in four divided doses (≥1 month).

Prescriber Checklist:

• Calculate paediatric dose by weight and use the correct suspension strength.
• Verify renal function before prescribing to older patients.
• Advise patients to complete the full course and what to do if a dose is missed.

Patient tip: take the missed dose as soon as remembered unless it is close to the next scheduled dose, and never double up.

Interactions Overview (Food, Drink, Medicines)

Patients often worry whether nitrofurantoin interacts with alcohol or other medicines.

Nitrofurantoin has relatively few direct pharmacokinetic interactions but caution is advised when co‑prescribing other drugs associated with peripheral neuropathy or pulmonary toxicity.

Examples of high‑risk drug categories include certain chemotherapeutic agents and prolonged use of neurotoxic antibiotics where adverse events may be additive.

Alcohol does not cause a disulfiram‑type reaction with nitrofurantoin, but it can increase nausea and reduce adherence.

Advise patients to mention herbal remedies and OTC medicines, and check G6PD status where appropriate.

High‑Risk Interaction Categories (Bulleted):

• Drugs causing or worsening peripheral neuropathy.
• Cytotoxic agents with recognised neurotoxicity.
• Agents with overlapping pulmonary toxicity where possible.

Counselling Points:

• Advise reporting new breathlessness, cough or neurologic symptoms promptly.
• Encourage patients to report suspected adverse reactions via the MHRA Yellow Card scheme.
• Reassure that usual beverages such as tea and coffee have no major interaction with nitrofurantoin.

Cultural Perceptions And Patient Habits (UK Patient Behaviour)

Many patients come to the pharmacy expecting quick relief and clear advice.

UK patients commonly use NHS 111, NHS.uk and community pharmacists at Boots, LloydsPharmacy and independent chemists for triage and counselling on urinary infections.

Online forums such as Patient.info and Mumsnet show mixed perceptions, with many praising nitrofurantoin’s effectiveness and others concerned about gastrointestinal side effects or rare long‑term problems.

Trust in pharmacist counselling remains high, and electronic prescriptions with online pharmacy delivery are increasingly used for repeat prophylaxis under clinician oversight.

Pharmacists and prescribers routinely reassure patients about benign brown urine and explain the rationale for renal screening in older patients.

Common Patient Concerns (Bulleted):

• Is it safe in pregnancy and for babies?
• Why does my urine change colour?
• How long before I feel better?

Trusted UK Information Sources:

• NHS.uk for patient guidance on urinary tract infections.
• MHRA for safety communications and Yellow Card reporting.
• Local formularies and GP practice leaflets for prescribing pathways.

Availability And Pricing Patterns (Boots, Lloyds, Superdrug, NHS)

People want to know whether nitrofurantoin is easy to obtain and how much it costs.

Nitrofurantoin is prescription only throughout the UK and supplied through community pharmacies including Boots, LloydsPharmacy, Superdrug and independent chemists.

There is a growing number of registered online pharmacies offering electronic prescription handling and home delivery.

On the NHS, nitrofurantoin attracts the standard prescription charge in England, while prescriptions are free in Scotland and Wales and for many patient groups in Northern Ireland.

Private purchase prices vary by brand and retailer; generics tend to be cheaper than branded modified‑release products such as Macrobid.

Pricing And Availability Summary:

• NHS supply follows standard prescription rules and regional differences apply to charges.
• Private retail prices for generics are typically lower than for branded 100 mg extended‑release capsules.
• Check the NHS Electronic Prescription Service for local dispensary options and delivery arrangements.

In our online pharmacy, macrodantin is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Comparable Medicines And Prescribing Preferences (NHS Choices)

Clinicians often weigh nitrofurantoin against fosfomycin and trimethoprim when selecting therapy for cystitis.

Common alternatives in NHS practice include fosfomycin as a single‑dose option, trimethoprim, co‑trimoxazole and pivmecillinam where available.

Choice depends on local resistance patterns, allergy history, renal function and infection site.

Nitrofurantoin is favoured for uncomplicated cystitis because of low resistance and a narrow urinary spectrum that spares broad systemic flora.

Fosfomycin is useful as a single‑dose outpatient therapy and is convenient when adherence is a concern.

For pyelonephritis or suspected systemic infection, fluoroquinolones or beta‑lactams selected by sensitivity are the preferred options.

Pros And Cons Checklist:

• Nitrofurantoin: strong urinary activity, multi‑day dosing, low resistance; not suitable for upper tract infections.
• Fosfomycin: single‑dose convenience, good for adherence; variable availability and resistance considerations.
• Trimethoprim: simple dosing but rising resistance in community E. coli reduces empirical reliability.

Guidance: culture recurrent infections and consider specialist referral if there is treatment failure or complex comorbidity.

Frequently Asked Questions (NHS Patient Questions)

Patients ask straightforward questions that pharmacists can answer quickly.

Is nitrofurantoin safe in pregnancy?

It is generally avoided in the last weeks of pregnancy from 38 weeks because of a small risk of neonatal haemolysis, and should be used only when benefits outweigh risks following antenatal guidance.

Can I drink alcohol while taking nitrofurantoin?

There is no formal contraindication, but alcohol can worsen gastrointestinal side effects and may affect adherence, so moderation is advised.

Why did my urine turn brown?

Brown urine is a benign metabolite effect of nitrofurantoin and patients should be reassured that it is expected.

What if I miss a dose?

Take the missed dose as soon as remembered unless it is nearly time for the next dose; do not double up on doses.

Encourage patients to consult NHS.uk and report suspected adverse events via the MHRA Yellow Card scheme.

Guidelines For Proper Use (Pharmacist Counselling & NHS Support)

Pharmacist counselling should be concise, structured and documented in the patient record where possible.

Confirm the indication and pregnancy status, review renal function and allergy history before supplying nitrofurantoin.

Explain the dosing schedule, expected duration and emphasise completion of the full course unless advised otherwise by the prescriber.

Counsel patients about common side effects including gastrointestinal upset and brown urine, and warn about serious but rare signs such as breathlessness, new neuropathy or jaundice.

Advise patients to seek urgent care if they develop severe respiratory symptoms, progressive weakness or yellowing of the skin or eyes.

For long‑term prophylaxis, recommend regular review with renal monitoring and reassessment of risks and benefits.

Pharmacist Counselling Checklist:

• Confirm pregnancy status and renal function where relevant.
• Review current medicines for neuropathy or pulmonary risk.
• Explain dose, duration and what to do for missed doses.
• Advise to stop and seek immediate care for breathlessness, new neuropathy or jaundice.

Encourage Yellow Card reporting for any suspected adverse drug reactions to support ongoing safety monitoring.

Delivery Across United Kingdom